Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 6;14(9):2314.
doi: 10.3390/cancers14092314.

CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy

Affiliations
Review

CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy

Rosanna Mezzapelle et al. Cancers (Basel). .

Abstract

CXCR4 is a G-Protein coupled receptor that is expressed nearly ubiquitously and is known to control cell migration via its interaction with CXCL12, the most ancient chemokine. The functions of CXCR4/CXCL12 extend beyond cell migration and involve the recognition and disposal of unhealthy or tumor cells. The CXCR4/CXCL12 axis plays a relevant role in shaping the tumor microenvironment (TME), mainly towards dampening immune responses. Notably, CXCR4/CXCL12 cross-signal via the T and B cell receptors (TCR and BCR) and co-internalize with CD47, promoting tumor cell phagocytosis by macrophages in an anti-tumor immune process called ImmunoGenic Surrender (IGS). These specific activities in shaping the immune response might be exploited to improve current immunotherapies.

Keywords: ACKR3; BCR; CD47; CXCL12; CXCR4; ImmunoGenic Surrender; TCR; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

M.E.B. is founder and part owner of HMGBiotech, and L.S.C. was supported by HMGBiotech. The other authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
CXCR4 membrane interactors and CXCL12-activated signal transduction pathways. (A) CXCL12 binding to CXCR4 leads to the activation of G protein-dependent signaling, MAPK, PI3K and PLC pathways, resulting in diverse biological outcomes such as calcium mobilization, cell proliferation, differentiation, migration and adhesion. CXCR4 can form a heterodimer with ACKR3 (CXCR7), which contributes to modulate CXCL12/CXCR4 signaling. ACKR3 impairs CXCR4-mediated G-protein activation and calcium responses. (B) In T cells, CXCR4 interacts with CD3/TCR. The activation of CXCR4 by CXCL12 induces the formation of the immunological synapsis with antigen presenting cells (APCs) and the activation of the RAS-ERK pathway. The interaction of the TCR with CXCR4 causes the phosphorylation of CXCR4-S339, which leads to PREX-Rac1 activation and to cytokine synthesis and secretion. (C) CXCR4 and CD47 are in contact in cancer cells; the binding to CXCR4 of CXCL12 or BoxA, a truncated form of HMGB1, promotes co-internalization of CXCR4-CD47. Reduction of surface CD47 impairs its recognition by SIRPα, allowing tumor cell phagocytosis by macrophages.
Figure 2
Figure 2
CXCL12 induces the internalization of the CXCR4-CD47 complex. CXCR4 and CD47 are in physical contact on the surface of untreated tumor cells (AB1-B/c-LUC mesothelioma cells, stained green with phalloidin; CXCR4-CD47 Proximity Ligation Assay signal, red). Overnight treatment with CXCL12 causes the almost complete disappearance of the CXCR4-CD47 signal from the cell surface. See [75] for details.

Similar articles

Cited by

References

    1. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392:565–568. doi: 10.1038/33340. - DOI - PubMed
    1. Hughes C.E., Nibbs R.J.B. A guide to chemokines and their receptors. FEBS J. 2018;285:2944–2971. doi: 10.1111/febs.14466. - DOI - PMC - PubMed
    1. Stein J.V., Nombela-Arrieta C. Chemokine control of lymphocyte trafficking: A general overview. Immunology. 2005;116:1–12. doi: 10.1111/j.1365-2567.2005.02183.x. - DOI - PMC - PubMed
    1. Ono S.J., Nakamura T., Miyazaki D., Ohbayashi M., Dawson M., Toda M. Chemokines: Roles in leukocyte development, trafficking, and effector function. J. Allergy Clin. Immunol. 2003;111:1185–1199. doi: 10.1067/mai.2003.1594. - DOI - PubMed
    1. Bachelerie F., Graham G.J., Locati M., Mantovani A., Murphy P.M., Nibbs R., Rot A., Sozzani S., Thelen M. New nomenclature for atypical chemokine receptors. Nat. Immunol. 2014;15:207–208. doi: 10.1038/ni.2812. - DOI - PubMed